Clinical evaluation of prazosin in symptomatic benign prostatichyperplasia - An Indian experience

Indian Journal of Pharmacology

Volumn 29, Issue 6, 1997, Pages 420-425

  Basalingappa, S ^a   Ignatius, J Xavier ^b   Madappa, K M ^c  

^a JSS COLLEGE OF PHARMACY   (India)

^b JSS MEDICAL COLLEGE   (India)

^c JSS Hospital   (India)

Author keywords

Benign prostatic hyperplesia; Clinical evaluation; Prazosin

Indexed keywords

PRAZOSIN;

ADULT; AGED; ARTICLE; BLADDER IRRITATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; URINARY TRACT OBSTRUCTION; UROFLOWMETRY;

EID: 0031457795     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Smith RA, Wake R, Soloway MS. Benign Prostatic Hyperplasia. Universal problem among aging men. Post grad-Med 1988;83:79-85.
2. Chappie CR, Noble JG, Milroy EJG. Comparative study of selective alpha-1 adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993;12:822-5.
3. Emil A Tanagho, Aninch MC. Smith's general urology. Neoplasms of the prostate gland.13th Edition. USA: Lange Medical Book Publisher, 1992:379.
4. Bruskewitz RC, Larsen EH, Madsen PO. Three year follow up urinary symptoms after trans urethral resection of the prostate. J Urol 1986;136:613-5.
5. Meyhoff HH. Transurethral versus transvesical Prostatectomy: Clinical, urodynamic, renographic and economic aspects: a randomised study. Scand J Urol Nephrol 1987; 102:1-26.
6. Roos NP, Wennberg JE, Malenka DJ. Mortality and reoperation after open and transurethral resection of the Prostate for benign Prostatic hyperplasia. N Eng J Med 1989;320:1120-24.
7. Ball AJ, Feneley RCL, Abrams PH. The natural history of untreated prostatism. Br J urol 1981;53:613-6.
8. Cain M, Shlomo R, Marcia Z. Adrenergic and Cholinergic receptors in human prostate, prostatic capsule and bladderneck. Br J Urol 1975;47:193-202.
9. Thien T, Delaere KP, Debruyne FMJ, Koene RAP. Urinary incontinence caused by Prazosin. Br Med J 1978;1:622-3.
10. Buzelin JM, Hebert M, Blondin P, and the PRAZALF group. Alpha blocking treatment with Alfuzosin in symptomatic benign prostatic hyperplasia:comparative study with prazosin. Br J Urol 1973;72:922-7.
11. Emil A, Tanagho, Jack W.Ac.A (eds). Smith's General Urology, 13th ed, U.S.A. Prentice: Hall International Inc., 1992:383.
12. Jardin A, Bensadoun MC, Delauche CP, Attali P and the BPHALF group. Long term treatment of Benign prostatic hyperplasia with Alfuzosin: a 12-18 month assessment. Br J Urol 1993;72:615-20.
13. Stanaszek WF, Kellerman B, Brogden RN, Romankiewicz. Prazosin update. Drugs 1983;25:339-84.
14. Lepor H. Role of alpha adrenergic blocker in the treatment of benign prostatic hyperplasia. Prostate 1990;3:75-84.
15. Lepor H. Alpha adrenergic antagonist for the treatment of symptomatic benign prostatic hyperplasia. Int J Clin Pharmacol Ther Toxicol 1989;27:151-5.
16. Chapple CR, Christmas TJ, Milroy EJG. A twelve week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int 1990;45:47-55.
17. Martorana G, Giberti, Damonte P. The effect of prazosin in benign prostatic obstruction. A placebo controlled double blind study. IRCS Med Sci 1984;12:11-2.
18. Hedlund H, Andersson KE. Effects of Prazosin in patients with benign prostatic obstruction. J Urol 1983;130:275-8.
19. Kirby RS, Coppinger SWC, Corcoran MO. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 1987;60:136-42.